FOLH1 and carcinoma: New options to develop innovative diagnostic and therapeutic approaches for the treatment of these aggressive carcinomas have arisen in the field of theranostics and, in particular, by detecting prostate-specific membrane antigen (PSMA) [1,5,13,14,15,16].